Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21635517 | 0.85 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1MAPTF10 | |
| SCHEMBL9615374 | 0.85 | RAB9A (0.58) | RAB9ASMN1; SMN2NPC1MAPTF10 | |
| SCHEMBL12804435 | 0.83 | MEN1 (0.50) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL9835549 | 0.83 | RAB9A (0.54) | RAB9ASMN1; SMN2NPC1MAPTF10 | |
| SCHEMBL167053 | 0.81 | GAA (0.67) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL28238289 | 0.81 | KMT2A (0.53) | RAB9ASMN1; SMN2NPC1MAPTKMT2A | |
| SCHEMBL3032397 | 0.80 | TDP1 (0.56) | MAPTF10IKBKBMEN1KMT2A | |
| Oxalic Acid SCHEMBL20984713 | 0.79 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1MAPTF10 | |
| SCHEMBL28278861 | 0.79 | KDM4E (0.51) | RAB9ASMN1; SMN2NPC1MAPTNFKB1 | |
| SCHEMBL5317475 | 0.78 | ALDH1A1 (0.71) | RAB9ASMN1; SMN2NPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611806-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Ascepion Pharmaceuticals, Inc. (CN) | 2013-07-10 | — | — | EP | claimed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | claimed |
| EP-3652180-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | Dart NeuroScience LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-111094293-A | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | 达特神经科学有限公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| EP-2611806-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Ascepion Pharmaceuticals, Inc. (CN) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | disclosed |
| US-7429598-B2 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| CN-1681507-A | Spiro-fused quinazolinones and their use as phosphodiesterase inhibitors | WARNER LAMBERT CO (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542694-A1 | NEW SPIROCONDENSED QUINAZOLINONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-06-03 | — | — | US | disclosed |
| WO-2004026818-A1 | NEW SPIROCONDENSED QUINAZOLINONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1400244-A1 | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | Warner-Lambert Company LLC (US) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | PDE3A, PDE5A, PDE3B | RAB9A 883/4885SMN1; SMN2 3200/4885NPC1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.